Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 2,514 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Osteoarthritis, Knee
Interventions: XT-150; Biological
Lead sponsor: Xalud Therapeutics, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Napa, California

Conditions: Healthy
Interventions: Lamotrigine, BI 409306, Placebo, BI 425809; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Long Beach, California • Marlton, New Jersey

Conditions: Visual Acuity
Interventions: Test Contact Lens, Control Contact Lens; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 7
States / cities: Birmingham, Alabama • Jacksonville, Florida • Sarasota, Florida + 4 more

Conditions: Pharmacokinetics
Interventions: Milademetan, Itraconazole, Posaconazole; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Visual Acuity
Interventions: senofilcon A Multifocal, senofilcon A Sphere, etafilcon A Multifocal, etafilcon A Sphere; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 6
States / cities: Orlando, Florida • East Lansing, Michigan • Raytown, Missouri + 3 more

Conditions: Healthy
Interventions: Midazolam, Selpercatinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Left Ventricular Ejection Fraction, Heart Failure (HF), Left Bundle-Branch Block
Interventions: LB-CRT, BIV-CRT; Device
Lead sponsor: Inova Health Care Services; Other
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Durham, North Carolina • Falls Church, Virginia

Conditions: Traumatic Brain Injury, Aging Disorder, Magnetic Resonance Imaging (MRI)
Interventions: Hypercapnia task performed during fMRI; Other
Lead sponsor: Andrew Mayer; Other
Eligibility: 18 Years to 82 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Vaping, Nicotine Absorption
Interventions: E-cigarette, P4M3-1.7%, P4M3-1.7%LA, P4M3-3%LA, P4M3-4%LA; Other
Lead sponsor: Philip Morris Products S.A.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Asthma
Interventions: Fluticasone Propionate Formulation 1, Fluticasone Propionate Formulation 2, Fluticasone Propionate Formulation 3*; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Tumor, Cancer
Interventions: AZD6244; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV Infections
Interventions: GSK3739937 (PIB), Placebo, GSK3739937 (Tablet); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity &Amp; Overweight
Interventions: Freeze-dried grape powder, Placebo powder; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Pulmonary Cystic Fibrosis
Interventions: Placebo, QBW276; Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: New York, New York • Dallas, Texas

Conditions: Breast MRI
Interventions: Standard of care contrast agent, provided in split dose, Breast MRI; Drug · Diagnostic Test
Lead sponsor: Manojkumar Saranathan; Other
Eligibility: 30 Years to 89 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Spinal Cord Injury
Interventions: SCI Reinvention Protocol Participants, Waitlist Group; Behavioral · Other
Lead sponsor: Craig Hospital; Other
Eligibility: 18 Years to 100 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Metastatic Melanoma, BRAF V600 Mutation Positive
Interventions: Itraconazole, Rifampin, Vemurafenib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Volunteers, Overweight, Obesity
Interventions: NNC9204-1177, Cocktail of 5 already approved drugs; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Cabotegravir 30 mg current formulation, Cabotegravir 30 mg micronized new formulation 500 M, Cabotegravir 30 mg unmicronized new formulation 500 U, Cabotegravir 30 mg micronized new formulation 650 M, Cabotegravir 30 mg unmicronized new formulation 650 U; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Non-small Cell Lung Cancer
Interventions: M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 4
States / cities: Bethesda, Maryland • Hershey, Pennsylvania • Greenville, South Carolina + 1 more

Conditions: Healthy Volunteers
Interventions: Itraconazole, Rifampin, Golcadomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 2
States / cities: Atlanta, Georgia • Lenexa, Kansas

Conditions: Respiratory Insufficiency, Respiratory Failure, Mechanical Ventilation Complication
Interventions: Patients given EMV Ventilation; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteer
Interventions: GSK1349572, Placebo, Omeprazole; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: Lenvatinib 10 mg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Las Vegas, Nevada

Search by objective public record fields.

Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain

A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine

Clinical Evaluation of Approved Contact Lenses

Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants

Clinical Evaluation of a Reusable Multifocal Optical Design in a Presbyopic Population

A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants

REsynchronization Comparison In LBBB and Normal or Mildly Reduced VENTricular Function With CRT (REINVENT-CRT)

Carbon Dioxide Administration and Brain Waste Clearance

Study to Investigate the Nicotine Pharmacokinetic Profiles and Pharmacodynamic Effects of P4M3 Variants

Sensitivity of Pharmacokinetics to Differences in Aerodynamic Particle Size Distribution

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers

Effects of Grape Consumption on the Immune-Gut Axis in Obesity

Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis

Low-dose Imaging TechniquE in Breast MRI

Re-Inventing Yourself After Spinal Cord Injury

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)

A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants

Entrainment-Based Mechanical Ventilation

GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study

Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers